Dennis, Susan J.O’Kennedy, Martha M.Rutkowska, DariaTsekoa, TsepoLourens, Carina W.Hitzeroth, Inga I.Meyers, Ann E.Rybicki, Edward P.2019-02-082019-02-082018-10-11Dennis, S.J., O'Kennedy, M.M., Rutkowska, D. et al. 2018, 'Safety and immunogenicity of plant‑produced African horse sickness virus‑like particles in horses', Veterinary Research, vol. 49, art. 105, pp. 1-6.0928-4249 (print)1297-9716 (online)10.1186/s13567-018-0600-4http://hdl.handle.net/2263/68427Additional file 1. Virus neutralising antibody titers and VP7 iELISA scores of VLP-vaccinated and control horse sera. Pre- and postvaccination sera were assayed for neutralisation capability against AHSV 5, AHSV 8 and AHSV 4. Sheep serum from animals vaccinated with live AHS virus was used as a positive control. The pre- and post-vaccination iELISA S/P scores of serum sampled prior to vaccination and 41 days post-vaccination are shown in the right hand column. High positive control sera pooled from vaccinated horses inoculated with live attenuated vaccine (bottle 1) obtained from OBP, was used as a positive control.African horse sickness (AHS) is caused by multiple serotypes of the dsRNA AHSV and is a major scourge of domestic equids in Africa. While there are well established commercial live attenuated vaccines produced in South Africa, risks associated with these have encouraged attempts to develop new and safer recombinant vaccines. Previously, we reported on the immunogenicity of a plant-produced AHS serotype 5 virus-like particle (VLP) vaccine, which stimulated high titres of AHS serotype 5-specific neutralizing antibodies in guinea pigs. Here, we report a similar response to the vaccine in horses. This is the first report demonstrating the safety and immunogenicity of plant-produced AHS VLPs in horses.en© The Author(s) 2018. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License.AfricaAfrican horse sickness (AHS)Virus-like particle (VLP)Horse (Equus caballus)SafetyImmunogenicityVaccinesArticle